|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on August 1, 2002; DOI 10.1182/blood-2001-12-0264.
NEOPLASIA
From the Division of Environmental Health Sciences,
School of Public Health, University of California, Berkeley; the
Division of Oncology, The Children's Hospital of Philadelphia, and the
Department of Pathology and Laboratory Medicine and the Department of
Pediatrics, University of Pennsylvania School of Medicine,
Philadelphia, PA.
An inactivating polymorphism at position 609 in the NAD(P)H:quinone
oxidoreductase 1 gene (NQO1 C609T) is associated with an
increased risk of adult leukemia. A small British study suggested that
NQO1 C609T was associated with an increased risk of infant leukemias with MLL translocations, especially infant acute
lymphoblastic leukemia (ALL) with t(4;11). We explored NQO1 C609T
as a genetic risk factor in 39 pediatric de novo and 18 pediatric
treatment-related leukemias with MLL translocations in the
United States. Children with de novo B-lineage ALL without
MLL translocations and a calculation of the expected
genotype distribution in an ethnically matched population of
disease-free subjects served as the comparison groups. Patients with de
novo leukemias with MLL translocations were significantly more likely to be heterozygous at NQO1 C609T (odds ratio
[OR] = 2.77, 95% confidence intervals [CI] 1.17-6.57;
P = .02), and significantly more likely to have low/null
NQO1 activity than patients with de novo B-lineage ALL without
MLL translocations (OR = 2.47, 95% CI 1.08-5.68;
P = .033). They were also significantly more likely to
have low/null NQO1 activity than expected in an ethnically matched
population of disease-free subjects (OR = 2.50, P = .02). Infants younger than 12 months old at diagnosis
of leukemia with t(4;11) were most likely to have low/null NQO1
activity (OR > 10.0). Conversely, the distribution of
NQO1 genotypes among patients with treatment-related
leukemias with MLL translocations was not statistically
different than in the comparison groups. The inactivating NQO1
polymorphism is associated with an increased risk of de novo
leukemia with MLL translocations in infants and children.
(Blood. 2002;100:4590-4593) NAD(P)H:quinone oxidoreductase 1 (NQO1)
protects cells against oxidative stress and toxic
quinones.1,2 A cytosine to thymine (C Study subjects and biologic samples
There were 39 patients diagnosed with de novo leukemia characterized by
translocation of the MLL gene at chromosome band 11q23, and
18 with treatment-related leukemia with MLL translocations. We examined 56 patients with de novo B-lineage ALL without
MLL gene rearrangement as a comparison population with a
common pediatric cancer. The demographic features of these patients are
shown in Table 1. The 39 MLL(+) de novo cases were diagnosed from birth to 18 years,
5 months of age. The karyotypes were previously
described.13,17,18 There were 19 ALL cases, including one
case of T-cell ALL; 17 AML cases; and 3 biphenotypic cases. The
morphology was French-American-British (FAB) M4
(myelomonocytic) or FAB M5 (monoblastic) in 13 cases of AML and in one
of the biphenotypic cases. There were 16 patients with ALL, 12 patients
with AML, and all 3 patients with biphenotypic leukemia who were
diagnosed before 12 months of age, and 1 patient with AML who was
diagnosed at age 15 months; these 32 patients were considered infants.
Of the 32 infants, 7 were diagnosed at birth. In all cases
there was evidence of MLL gene rearrangement by Southern
blot analysis.13 The MLL translocations were
characterized cytogenetically and/or, in some cases, by panhandle
polymerase chain reaction (PCR) approaches.13,17,19-21
The 18 MLL(+) treatment-related leukemias and prior DNA topoisomerase II inhibitor exposures have also been described.14,18,22 The ages of the patients ranged from 3 years, 7 months to 17 years, 2 months when the diagnosis of treatment-related leukemia was made. There were 13 treatment-related leukemia patients who presented with AML, 2 with myelodysplasic syndrome (MDS), 2 with ALL, and 1 was biphenotypic. The detection of MLL translocations was the same as in the de novo cases.14,18,22 The 56 patients with MLL(-) de novo B-lineage ALL were included in prior studies.15,18 The age at diagnosis in 48 of these patients for whom data were available ranged from 1 year, 4 months to 19 years, 11 months. NQO1 genotype analysis All laboratory personnel were blinded to case-control status. NQO1 genotypes were analyzed as previously described.10 Wild-type (CC) individuals were assigned to the high activity category. Individuals who were heterozygous (CT) or homozygous (TT) for the C609T polymorphism were assigned to the low/null NQO1 activity category because the homozygous group was too small to analyze alone.Statistical analysis NQO1 genotype frequencies in patients with MLL(+) de novo or treatment-related leukemias were compared with NQO1 genotype frequencies in children with MLL(-) de novo B-lineage ALL. The expected NQO1 allele frequencies in a disease-free population ethnically matched to the MLL(+) de novo cases were calculated from previously published data5,8,9,23 and used as a second comparison group. The significance of the difference between groups was determined by constructing 2-by-2 tables and generating crude odds ratios and 95% confidence intervals using Cornfield approximations, and 2-tailed P values were calculated using Fisher exact methods. All results were considered statistically significant if the 2-tailed P value was less than .05. The analysis was carried out using the statistical computer program STATA (Stata Corporation, College Station, TX).
NQO1 genotypes in the 3 groups including pediatric
patients with MLL(+) de novo leukemia (n = 39), pediatric
patients with MLL(+) treatment-related leukemia (n = 18),
and pediatric patients with MLL(-) de novo B-lineage ALL
(n = 56), are shown in Table 2. In the
patients with MLL(+) de novo leukemia, there was a strong
shift toward heterozygosity at the NQO1 C609T allele. These patients were significantly more likely to be heterozygous at NQO1 C609T than patients in the comparison group with
MLL(-) de novo B-lineage ALL (OR = 2.77, 95% CI
1.17-6.57; P = .02). Assigning individuals who were
heterozygous (CT) or homozygous (TT) for the C609T
polymorphism to the low/null NQO1 activity category revealed that
patients with MLL(+) de novo leukemia were significantly more likely to have low/null NQO1 activity than patients with MLL(-) de novo B-lineage ALL (OR = 2.47, 95% CI
1.08-5.68; P = .033) or than would be expected in an
ethnically matched population of disease-free subjects (OR = 2.50,
P = .02) (Table 2). This almost identical finding of an
increased OR of approximately 2.5 when the MLL(+) group is
compared with 2 different groups shows that bias due to ethnic
differences or population stratification is unlikely to explain
the findings.
There was no difference in the susceptibility of males and females with
MLL(+) de novo leukemia (OR = 1.07, 95% CI 0.29-3.86; P = .92), indicating that the NQO1 genotype
effect is sex independent. When the MLL(+) de novo
cases were analyzed by lineage, a statistically significant association
of NQO1 C609T was only observed with ALL (OR = 3.35)
(Table 3). The sample size of patients
with MLL(+) de novo AML was too small to make strong
inferences.
The 39 patients with MLL(+) de novo leukemias were further analyzed by age at diagnosis, and by whether t(4;11) was observed in the karyotype (Table 3). Of the 39 MLL(+) de novo cases, 32 were classified as infant leukemias as described above. The OR for NQO1 low/null genotypes among these 32 infant cases compared with the 56 cases of MLL(-) de novo B-lineage ALL was 2.25, which is similar to the OR of 2.47 for the entire group of patients with MLL(+) de novo leukemia compared with the same comparison group. For the 7 patients who were more than 2 years old at diagnosis of MLL(+) de novo leukemia, the OR for NQO1 low/null genotypes was 3.86 compared with the same comparison group with MLL(-) de novo B-lineage ALL, but this was not significantly different than the OR of 2.25 observed for the infants. The most common MLL translocation in infant ALL is t(4;11)(q21;q23),24,25 which fuses MLL with AF-4.26 In the de novo leukemias in the present study, the karyotype revealed t(4;11) in 9 cases of ALL, 2 cases of AML, and one biphenotypic leukemia. NQO1 low/null genotypes were present in 10 (83.3%) of these 12 cases, and the OR compared with the control population of children with MLL(-) de novo B-lineage ALL was 7.73 (95% CI 1.7 to infinity) (Table 3). This result is highly statistically significant (P = .006). When only those infants diagnosed with leukemia with t(4;11) before 12 months of age (n = 8) were analyzed, the OR was even higher at 10.82, and also was highly statistically significant (Table 3). Panhandle PCR and/or cDNA panhandle analysis has been performed in 8 of the 12 cases with cytogenetic evidence of t(4;11) and, in each of the 8 cases, there was evidence of a translocation fusing MLL to AF-4.19,21 There were 2 other de novo leukemias with molecular evidence of a translocation fusing MLL to AF-4. In one case the karyotype was normal13,19; in the other case, there were no mitoses in the diagnostic marrow for karyotype analysis but the karyotype at relapse was complex and included evidence of t(4;11).13,17,21 Both cases were infant ALL and both had low/null NQO1 activity, such that when these cases were included in the analysis of leukemias with t(4;11), the association of low/null NQO1 activity with t(4;11) became even stronger in the infants less than 12 months old at diagnosis (OR = 13.91) (Table 3). The distribution of NQO1 genotypes among patients with treatment-related leukemias was not statistically different from that found in patients with MLL(-) de novo B-lineage ALL with respect to either low/null NQO1 activity (OR = 0.59; 95% CI 0.19-1.85; P = .38) or the frequency of heterozygosity (OR = 0.73; 95% CI 0.23-2.3; P = .6). Moreover, the OR and trend toward heterozygosity appeared to be in the opposite direction compared with that found in pediatric patients with MLL(+) de novo leukemias. This may be related to the predominance of other MLL translocations, especially t(9;11) and t(11;19), in the treatment-related cases included in this study versus the predominance of t(4;11) in the MLL(+) de novo cases or, alternatively, to differing etiologies.
We have shown that the inactivating NQO1 C609T polymorphism is associated with an increased risk of leukemia with MLL translocations in infants and children in a United States population. These findings are almost identical to those of Wiemels et al12 in a population of British infants and further support the hypothesis that low/null NQO1 activity is a risk factor for infant leukemias harboring MLL translocations. The odds ratios between 7.7 and 13.9 in the patients with de novo leukemias with t(4;11) compared with a population of children with MLL(-) de novo B-lineage ALL are consistent with the findings of Wiemels et al, who observed an 8-fold increased risk for infant leukemias with t(4;11) when using normal cord blood samples as controls.12 Moreover, in the present study, the odds ratios became even higher (10.82 to 13.91) when considering only infant leukemias with t(4;11). While the total number of subjects studied is still small and the confidence intervals quite wide, this analysis by karyotype may imply that there may be different risk factors for de novo leukemias harboring different MLL translocations. The reason why low/null NQO1 activity appears to be so strongly associated with the t(4;11) translocation in particular is unknown. However, the finding of the same NQO1 genotype-leukemia association in 2, albeit small, independent studies supports a role for NQO1 substrate(s) such as benzoquinone and related compounds and/or oxidative stress as causative factors in leukemias with MLL translocations, especially infant leukemias with t(4;11). Because similar MLL translocations are found in leukemias related to chemotherapy with DNA topoisomerase II inhibitors, DNA topoisomerase II has been implicated in the generation of MLL gene rearrangements (reviewed in Felix27). MLL translocations in infant leukemias arise in utero,28,29 and maternal prenatal consumption of food items containing DNA topoisomerase II inhibitors may increase the risk of infant AML.30,31 Flavonoids such as genistein, quercetin, and daidzein are examples of dietary DNA topoisomerase II inhibitors,32 and it has been shown that quercetin induces NQO1 gene expression.33 In addition, there are numerous potential dietary and environmental sources of the NQO1 substrate 1,4-benzoquinone,34 which potentially may interfere with the catalytic activity of DNA topoisomerase II35 or interact with DNA directly. Therefore, it is biologically plausible that the NQO1 genotype is a host factor that modulates the risk of leukemia in infants. Exactly how low/null NQO1 activity may contribute to the increased risk remains unknown, but these findings suggest that the pursuit of NQO1 substrate(s) as potential causative factors in infant leukemia is warranted. The present study also provides new information on the group of pediatric patients with treatment-related leukemias with MLL translocations. Although the sample size for this group was small, the results suggest that NQO1 does not have a protective role against MLL(+) leukemias arising after chemotherapeutic DNA topoisomerase II inhibitors, where the CYP3A4 wild-type genotype has been shown to confer susceptibility.18
We acknowledge the AML Cell Bank of the Children's Cancer Group for providing several of the de novo leukemias reported on herein.
Submitted December 18, 2001; accepted July 17, 2002.
Prepublished online as Blood First Edition Paper, August 1, 2002; DOI 10.1182/blood-2001-12-0264.
Supported by the National Foundation for Cancer Research and National Institutes of Health (NIH) grants P42ES04705 and P30ES01896 to M.T.S., NIH grants CA66140 and CA80175 to C.A.F., and the Joshua Kahan Foundation. L.L.N. was supported by a grant from the Associazione Italiana Ricerca sul Cancro (AIRC).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Martyn T. Smith, Division of Environmental Health Sciences, School of Public Health, 216 Earl Warren Hall, University of California, Berkeley, CA 94720-7360; e-mail: martynts{at}uclink.berkeley.edu.
1. Ernster L. DT-diaphorase: its structure, function, regulation, and role in antioxidant defence and cancer chemotherapy. In: Yagi K, ed. Pathophysiology of Lipid Peroxides and Related Free Radicals. Basel, Switzerland: S Karger; 1998:149-168. 2. Ross D. Quinone reductases. In: Guengerich FP, ed. Comprehensive Toxicology. Vol 3. New York, NY: Pergamon Press; 1997:179-197.
3.
Traver RD, Horikoshi T, Danenberg KD, et al.
NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.
Cancer Research.
1992;52:797-802 4. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 1999;9:113-121[Medline] [Order article via Infotrieve]. 5. Kelsey KT, Ross D, Traver RD, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer. 1997;76:852-854[Medline] [Order article via Infotrieve]. 6. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics. 1995;5:199-206[Medline] [Order article via Infotrieve]. 7. Schulz WA, Krummeck A, Rösinger I, Schmitz-Dräger BJ, Sies H. Predisposition towards urolithiasis associated with the NQO1 null-allele. Pharmacogenetics. 1998;8:453-454[Medline] [Order article via Infotrieve]. 8. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev. 1997;6:87-92[Abstract].
9.
Rothman N, Smith MT, Hayes RB, et al.
Benzene poisoning, a risk factor for hematologic malignancy, is associated with NQO1 609 C
10.
Larson RA, Wang Y, Banerjee M, et al.
Prevalence of the inactivating 609C
11.
Smith MT, Wang Y, Kane E, et al.
Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults.
Blood.
2001;97:1422-1426
12.
Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves MF.
A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions.
Cancer Res.
1999;59:4095-4099 13. Felix CA, Hosler MR, Slater DJ, et al. MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children. J Pediatr Hematol/Oncol. 1998;20:299-308[CrossRef][Medline] [Order article via Infotrieve].
14.
Felix CA, Hosler MR, Winick NJ, Masterson M, Wilson AE, Lange BJ.
ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children.
Blood.
1995;85:3250-3256 15. Felix CA, Poplack DG, Reaman GH, et al. Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol. 1990;8:431-442[Abstract]. 16. Nowell P, Finan J. Chromosome studies in preleukemic states. IV. Myeloproliferative versus cytopenic disorders. Cancer. 1978;42:2254-2261[CrossRef][Medline] [Order article via Infotrieve].
17.
Felix C, Kim C, Megonigal M, et al.
Panhandle PCR amplifies genomic translocation breakpoint involving unknown partner gene.
Blood.
1997;90:4679-4686
18.
Felix CA, Walker AH, Lange BJ, et al.
Association of CYP3A4 genotype with treatment-related leukemia.
Proc Natl Acad Sci U S A.
1998;95:13176-13181 19. Lo Nigro L, Rappaport E, Slater D, et al. Rapid isolation of genomic translocation breakpoints involving MLL and unknown AF-4 intronic sequences or MLL and unknown partner genes [abstract]. Proc ASCO. 1999;18:565a.
20.
Megonigal MD, Rappaport EF, Wilson RB, et al.
Panhandle PCR for cDNA: a rapid method for isolation of MLL fusion transcripts involving unknown partner genes.
Proc Natl Acad Sci U S A.
2000;97:9597-9602
21.
Raffini LJ, Slater DJ, Rappaport EF, et al.
Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6.
Proc Natl Acad Sci U S A.
2002;99:4568-4573
22.
Megonigal MD, Rappaport EF, Jones DH, et al.
Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias.
Proc Natl Acad Sci U S A.
1997;94:11583-11588 23. Traver RD, Siegel D, Beall HD, et al. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br J Cancer. 1997;75:69-75[Medline] [Order article via Infotrieve]. 24. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the U.S.: histology-specific incidence and trends, 1973-1992. J Pediatr Hematol/Oncol. 1997;19:428-432[CrossRef][Medline] [Order article via Infotrieve].
25.
Heerema NA, Sather HN, Ge J, Hilden JM, Trigg ME, Reaman GH.
Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) 26. Gu Y, Nakamura T, Alder H, et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila Trithorax, to the AF-4 gene. Cell. 1992;71:701-708[CrossRef][Medline] [Order article via Infotrieve]. 27. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol. 2001;36:525-535[CrossRef][Medline] [Order article via Infotrieve]. 28. Ford AM, Ridge SA, Cabrera ME, et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature. 1993;363:358-360[CrossRef][Medline] [Order article via Infotrieve]
29.
Gale K, Ford A, Repp R, et al.
Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal bloodspots.
Proc Natl Acad Sci U S A.
1997;94:13950-13954 30. Ross JA, Potter JD, Reaman GH, Pendergrass TW, Robison LL. Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group. Cancer Causes and Control. 1996;7:581-590[CrossRef][Medline] [Order article via Infotrieve]. 31. Ross JA. Maternal diet and infant leukemia: a role for DNA topoisomerase II inhibitors? Int J Cancer. 1998;11(suppl):26-28. 32. Corbett A, Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol. 1993;6:585-597[CrossRef][Medline] [Order article via Infotrieve]. 33. Valerio LG Jr, Kepa JK, Pickwell GV, Quattrochi LC. Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicology Letters. 2001;119:49-57[CrossRef][Medline] [Order article via Infotrieve]. 34. McDonald TA, Holland NT, Skibola C, Duramad P, Smith MT. Hypothesis: phenol and hydroquinone derived mainly from diet and gastrointestinal flora activity are causal factors in leukemia. Leukemia. 2001;15:10-20[CrossRef][Medline] [Order article via Infotrieve].
35.
Chen H, Eastmond DA.
Topoisomerase inhibition by phenolic metabolites: a potential mechanism for benzene's clastogenic effects.
Carcinogenesis.
1995;16:2301-2307
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  RE: "NQO1 POLYMORPHISMS AND DE NOVO CHILDHOOD LEUKEMIA: A HUGE REVIEW AND META-ANALYSIS" Am. J. Epidemiol., May 15, 2009; 169(10): 1280 - 1280. [Full Text] [PDF]
|
|
|
|
|
|
N. Guha, J. S. Chang, A. P. Chokkalingam, J. L. Wiemels, M. T. Smith, and P. A. Buffler THE AUTHORS REPLY Am. J. Epidemiol., May 15, 2009; 169(10): 1279 - 1279. [Full Text] [PDF]
|
|
|
|
|
|
M. Lanciotti and C. Dufour Re: "NQO1 POLYMORPHISMS AND DE NOVO CHILDHOOD LEUKEMIA: A HUGE REVIEW AND META-ANALYSIS" Am. J. Epidemiol., May 15, 2009; 169(10): 1278 - 1279. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Leone, L. Pagano, D. Ben-Yehuda, and M. T. Voso Therapy-related leukemia and myelodysplasia: susceptibility and incidence Haematologica, October 1, 2007; 92(10): 1389 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Infante-Rivard, J. K. Vermunt, and C. R. Weinberg Excess Transmission of the NAD(P)H:Quinone Oxidoreductase 1 (NQO1) C609T Polymorphism in Families of Children with Acute Lymphoblastic Leukemia Am. J. Epidemiol., June 1, 2007; 165(11): 1248 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bolufer, M. Collado, E. Barragan, J. Cervera, M.-J. Calasanz, D. Colomer, J. Roman-Gomez, and M. A. Sanz The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia Haematologica, March 1, 2007; 92(3): 308 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Healy, H. Belanger, P. Beaulieu, M. Lariviere, D. Labuda, and D. Sinnett Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia Blood, January 15, 2007; 109(2): 683 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Spector, S. M. Davies, L. L. Robison, J. M. Hilden, M. Roesler, and J. A. Ross Birth Characteristics, Maternal Reproductive History, and the Risk of Infant Leukemia: A Report from the Children's Oncology Group Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 128 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Spector, Y. Xie, L. L. Robison, N. A. Heerema, J. M. Hilden, B. Lange, C. A. Felix, S. M. Davies, J. Slavin, J. D. Potter, et al. Maternal Diet and Infant Leukemia: The DNA Topoisomerase II Inhibitor Hypothesis: A Report from the Children's Oncology Group Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 651 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Wilson and K. Olden The Environmental Genome Project: Phase I and Beyond Mol. Interv., June 1, 2004; 4(3): 147 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Pui, M. V. Relling, and J. R. Downing Acute Lymphoblastic Leukemia N. Engl. J. Med., April 8, 2004; 350(15): 1535 - 1548. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wakabayashi, A. T. Dinkova-Kostova, W. D. Holtzclaw, M.-I. Kang, A. Kobayashi, M. Yamamoto, T. W. Kensler, and P. Talalay Protection against electrophile and oxidant stress by induction of the phase 2 response: Fate of cysteines of the Keap1 sensor modified by inducers PNAS, February 17, 2004; 101(7): 2040 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Gilliland, C. T. Jordan, and C. A. Felix The Molecular Basis of Leukemia Hematology, January 1, 2004; 2004(1): 80 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Greaves, A. T. Maia, J. L. Wiemels, and A. M. Ford Leukemia in twins: lessons in natural history Blood, October 1, 2003; 102(7): 2321 - 2333. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
T) polymorphism at
position 609 in the NQO1 gene (NQO1 C609T)
produces a proline to serine substitution that destabilizes and
inactivates the enzyme.
) leukemias
a report of the Children's Cancer Group.
Leukemia.
1999;13:679-686